Schmidt M, Schler G, Gruensfelder P, Müller J, Hoppe F
Department of Otorhinolaryngology, University of Wuerzburg, Germany.
Head Neck. 2000 Aug;22(5):498-504. doi: 10.1002/1097-0347(200008)22:5<498::aid-hed9>3.0.co;2-w.
Urokinase-type plasminogen activator is important for matrix degradation and motility of cancer cells. For effective invasion, urokinase has to be associated with its cell surface receptor.(1)
We analyzed 33 head and neck squamous cell carcinomas (hnSCC) and 14 mucosal tissue samples for the expression of urokinase receptor using Northern hybridization and correlated expression levels to clinical and histopathologic data. Urokinase expression was determined by fibrin zymography.
The expression of urokinase receptor is significantly increased in hnSCC compared with adjacent mucosa. Expression levels in primary tumors show no statistically significant correlations to T staging, metastasis, recurrence, or differentiation stage of the resected tumors. Furthermore, there was no correlation between urokinase and urokinase receptor expression levels in SCC samples.
Urokinase receptor expression is increased in hnSCC, but it is not useful as a prognostic marker for the metastatic behavior of primary tumors. Comparison of our data with previously published reports is discussed.
尿激酶型纤溶酶原激活剂对于癌细胞的基质降解和运动能力很重要。为了实现有效的侵袭，尿激酶必须与其细胞表面受体相结合。（1）
我们使用Northern杂交分析了33例头颈部鳞状细胞癌（hnSCC）和14例黏膜组织样本中尿激酶受体的表达情况，并将表达水平与临床和组织病理学数据进行关联。通过纤维蛋白凝块溶解法测定尿激酶的表达。
与相邻黏膜相比，hnSCC中尿激酶受体的表达显著增加。原发性肿瘤中的表达水平与切除肿瘤的T分期、转移、复发或分化阶段无统计学显著相关性。此外，SCC样本中尿激酶和尿激酶受体的表达水平之间没有相关性。
hnSCC中尿激酶受体表达增加，但它不能作为原发性肿瘤转移行为的预后标志物。本文讨论了我们的数据与先前发表报告的比较。
